Gentex Corporation's Q4 Earnings Miss: A Detailed Analysis

Posted Feb 3 by John Deo

Gentex Corporation (NASDAQ:GNTX) reported earnings per share (EPS) of $0.39 and revenue of $541.6 million, mi

Source: Two Blokes Trading

Piper Sandler Companies (NYSE:PIPR) Surpasses Earnings and Revenue Estimates

Posted Feb 3 by John Deo

Piper Sandler Companies (NYSE:PIPR) reported an earnings per share (EPS) of $4.80, significantly beating the

Source: Two Blokes Trading

Venture Global, Inc. (NYSE:VG) IPO Marks a Significant Entry into the Public Market

Posted Feb 3 by John Deo

Venture Global, Inc. (NYSE:VG) is a prominent player in the liquefied natural gas (LNG) export industry. The c

Source: Two Blokes Trading

Pure Cycle Corporation's Financial Performance in Comparison

Posted Feb 3 by John Deo

Pure Cycle Corporation (NASDAQ:PCYO) is a company involved in water and land resource development. It focuses

Source: Two Blokes Trading

Interactive Brokers Group, Inc. (IBKR) Maintains Strong Market Position

Posted Feb 3 by John Deo

Goldman Sachs reaffirms its "Buy" rating for NASDAQ:IBKR, indicating confidence in the company's business mod

Source: Two Blokes Trading

Atlas Energy Solutions Inc. (NYSE: AESI) Announces Upsized Public Offering and Strategic Acquisition

Posted Feb 3 by John Deo

Atlas Energy Solutions Inc. (NYSE:AESI) aims to raise $264.5 million through an upsized underwritten public o

Source: Two Blokes Trading

Healthpeak Properties, Inc. (NYSE:DOC) Earnings Preview: A Deep Dive into Financial Health and Future Prospects

Posted Feb 3 by John Deo

Earnings per share (EPS) for Q4 2024 are expected to be $0.05 with projected revenue of approximately $691.8

Source: Two Blokes Trading

NVIDIA Corporation (NASDAQ:NVDA) Faces Challenges Amid AI Competition

Posted Feb 3 by John Deo

NVIDIA Corporation (NASDAQ:NVDA) stock drops by 17% due to concerns over DeepSeek's new AI model. Citigroup m

Source: Two Blokes Trading

Akero Therapeutics Receives Overweight Rating from Barclays

Posted Feb 3 by John Deo

Barclays upgraded Akero Therapeutics (NASDAQ:AKRO) to an "Overweight" rating, with a significant stock price

Source: Two Blokes Trading

Everest Group, Ltd. (NYSE: EG) Analysts' Perspectives and Financial Outlook

Posted Feb 3 by John Deo

The consensus price target for Everest Group, Ltd. (NYSE: EG) has increased from $412.5 to $453, indicating a

Source: Two Blokes Trading

Equity Residential (NYSE:EQR) Shows Positive Analyst Sentiment Amidst Urban Real Estate Demand

Posted Feb 3 by John Deo

The consensus price target for Equity Residential (NYSE:EQR) has been on a positive trend, indicating a moder

Source: Two Blokes Trading

Tempus AI, Inc. (NASDAQ: TEM) Quarterly Earnings Preview

Posted Feb 3 by John Deo

Tempus AI is set to release its quarterly earnings with an anticipated EPS of -$0.14 and expected revenue of

Source: Two Blokes Trading